Skip to content

The Potential of Psychedelics for End of Life and Palliative Care.

David B. Yaden, Sandeep M. Nayak, Natalie Gukasyan, Brian T Anderson, Roland R. Griffiths

Current Topics in Behavioral Neurosciences 2022 DOI: 10.1007/7854_2021_278 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Population Patients with life-threatening diagnoses
Topics Psilocybin End-of-life distress
Keywords End of life Palliative care Psychedelics
Citations 31
Key findings Psychedelics may provide clinicians with an additional psychopharmacological treatment in the context of end-of-life and palliative care.

Abstract

End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these contexts remain limited. In particular, psychological factors such as depression, existential distress, and well-being remain challenging to address with current medications. Here, we review recent research on the use of psychedelics in clinical settings with a particular focus on patients with life-threatening diagnoses. We propose that psychedelics may provide clinicians with an additional psychopharmacological treatment in the context of end of life and palliative care.

In the evidence

This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.

  • Argues that psychedelics may provide clinicians an additional psychopharmacological treatment for depression, existential distress, and well-being in end-of-life and palliative care.

    Synthesized

  • Proposes that psychedelics may provide clinicians with an additional psychopharmacological treatment for depression, existential distress, and well-being in end-of-life and palliative care, where current options are limited.

    Synthesized

Comparable studies

Other narrative reviews on psilocybin for end-of-life distress, most cited first.

Explore topics

By condition and practice